Engineering Immune Organoids to Study Pediatric Cancer

Recruiting now · Not applicable

Conditions studied: Brain Tumor, Kidney Tumor, Neuroblastoma, Sarcoma

In brief

To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)

Key facts

Study ID

NCT05890781

Run by

Gustave Roussy, Cancer Campus, Grand Paris

People needed

108

Starts

2023-05-12

Expected to finish

2028-05-01

Last updated by the study team

2026-02-09

Who can join

Age: any, up to 25. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied
• Medical suspicion or diagnosis of one of the following diseases, regardless of stage:
• Brain tumors
• Renal tumors
• Neuroblastoma
• Sarcomas
• Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
• Affiliated to a social security system or beneficiary of the same.

You may not qualify if…

• Any histology not mentioned in the inclusion criteria
• Adult patient or parents/guardians incapable/incapable of giving its/their consent
• Patients deprived of their liberty by a judicial or administrative decision

Where it is running

• Gustave Roussy — Villejuif, France (enrolling)
• Hopital Necker — Paris, Île-de-France Region, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.